Header

UZH-Logo

Maintenance Infos

Localized synovial sarcoma of the foot or ankle: A series of 32 Cooperative Weichteilsarkom Study Group patients


Scheer, Monika; Greulich, Michael; Loff, Steffan; Vokuhl, Christian; Feuchtgruber, Simone; von Kalle, Thekla; Münter, Marc; Stegmaier, Sabine; Sparber-Sauer, Monika; Kazanowska, Bernarda; Niggli, Felix; Fuchs, Jörg; Bielack, Stefan S; Klingebiel, Thomas; Koscielniak, Ewa (2019). Localized synovial sarcoma of the foot or ankle: A series of 32 Cooperative Weichteilsarkom Study Group patients. Journal of Surgical Oncology, 119(1):109-119.

Abstract

BACKGROUND
Synovial sarcoma of the foot/ankle is rare. Mutilating surgery is often discussed.
METHODS
Patients registered from 1981 to 2013 were analyzed. Cooperative Weichteilsarkom Studiengruppe (CWS) protocols recommend chemotherapy for all synovial sarcoma patients.
RESULTS
Thirty-two of 330 patients with localized synovial sarcoma had their tumor at the foot/ankle. Eleven of thirty-two tumors were >5 cm. Twenty were T1, 11 T2, and one TX, respectively. Eight (25%) patients underwent primary complete resection with free margins (Intergroup Rhabdomyosarcoma Study [IRS] I), 12 of 32 (38%) primary complete resection with positive margins (IRS II), and 12 of 32 (38%) had macroscopic residuals (IRS III). The best surgical result at any time was R0 in 19, R1 in 10 and R2 in one patient, and missing in two. Mutilation was documented in 14 of 32 (44%). Radiotherapy was conducted in 20 patients. All patients achieved a first complete remission. Five-year-event-free survival and overall survival rates were 80% and 86%, respectively. Four patients suffered local and four other metastatic recurrences. IRS and the best surgical result at any time did not correlate with survival. There was no prognostic difference between R0- and R1-resection.
CONCLUSION
Survival expectancies for patients with localized synovial sarcomas of the foot/ankle compare favorably to that of those with other affected sites.
DISCUSSION
Further studies are needed to set the limits of minimally required aggressiveness of local therapies.

Abstract

BACKGROUND
Synovial sarcoma of the foot/ankle is rare. Mutilating surgery is often discussed.
METHODS
Patients registered from 1981 to 2013 were analyzed. Cooperative Weichteilsarkom Studiengruppe (CWS) protocols recommend chemotherapy for all synovial sarcoma patients.
RESULTS
Thirty-two of 330 patients with localized synovial sarcoma had their tumor at the foot/ankle. Eleven of thirty-two tumors were >5 cm. Twenty were T1, 11 T2, and one TX, respectively. Eight (25%) patients underwent primary complete resection with free margins (Intergroup Rhabdomyosarcoma Study [IRS] I), 12 of 32 (38%) primary complete resection with positive margins (IRS II), and 12 of 32 (38%) had macroscopic residuals (IRS III). The best surgical result at any time was R0 in 19, R1 in 10 and R2 in one patient, and missing in two. Mutilation was documented in 14 of 32 (44%). Radiotherapy was conducted in 20 patients. All patients achieved a first complete remission. Five-year-event-free survival and overall survival rates were 80% and 86%, respectively. Four patients suffered local and four other metastatic recurrences. IRS and the best surgical result at any time did not correlate with survival. There was no prognostic difference between R0- and R1-resection.
CONCLUSION
Survival expectancies for patients with localized synovial sarcomas of the foot/ankle compare favorably to that of those with other affected sites.
DISCUSSION
Further studies are needed to set the limits of minimally required aggressiveness of local therapies.

Statistics

Citations

Altmetrics

Downloads

1 download since deposited on 13 Mar 2019
1 download since 12 months
Detailed statistics

Additional indexing

Contributors:and the other members of the Cooperative Weichteilsarkom Studiengruppe (CWS) Group
Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:January 2019
Deposited On:13 Mar 2019 16:15
Last Modified:13 Mar 2019 16:16
Publisher:Wiley-Blackwell Publishing, Inc.
ISSN:0022-4790
OA Status:Closed
Publisher DOI:https://doi.org/10.1002/jso.25284
PubMed ID:30421433

Download